Hematopoietic Stem Cell Transplantation Clinical Trial
Official title:
Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant
The purpose of this study is to determine whether vitamin D is effective in the prevention of graft-versus-host-disease after completion of allogeneic transplant.
The allogeneic transplant of haematopoietic cell is the only treatment option for many
malignant blood diseases. Unfortunately, the progression free survival and the quality of
life of transplanted patients is limited due to the development of graft-versus-host-disease
(GVHD).
The development of new prophylaxis strategies of GVHD based in the use of immunomodulator
agents (allowing the generation of an immunotolerance state and avoiding the use of
immunosuppression) is essential.
The GVHD is due to the cytotoxic effect of the donor lymphocytes T against healthy organs
and tissues of the receptor. Calcineurin inhibitor combined with methotrexate or antibodies
anti-lymphocytes T are used as standard prophylaxis. This type of antibodies has
demonstrated efficacy to reduce GVHD, but have not increased survival due to increasing the
risk of relapses and serious post-transplant infections.
Due to its interactions with VDR (vitamin D receptor) present in immune system cells,
vitamin D is able to inhibit the activation of dendritic cells and the proliferation and
production of cytokines by lymphocytes T. Based on this effect, the peri- and post-
transplant administration of vitamin D might decrease the risk of GVHD in allogeneic
transplanted patients, subsequently decreasing the immunosuppressant treatment requirements
and improving the prognosis of those patients.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00766883 -
Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT06148610 -
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
|
||
| Recruiting |
NCT04690933 -
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
|
||
| Completed |
NCT02564458 -
Fitness in Allogeneic Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT02543073 -
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT01714557 -
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT00701688 -
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
| Completed |
NCT00023530 -
Blood and Marrow Transplant Clinical Research Network
|
N/A | |
| Recruiting |
NCT04092309 -
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
|
N/A | |
| Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
| Completed |
NCT02663622 -
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
|
Phase 2 | |
| Recruiting |
NCT04937634 -
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT04203108 -
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
|
Phase 4 | |
| Completed |
NCT03654599 -
Effects of Digital Stories Intervention on Psychosocial Well-being
|
N/A | |
| Withdrawn |
NCT03279133 -
Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.
|
Phase 4 | |
| Completed |
NCT05151406 -
Myths and Misconceptions About HSCT in a Limited Resource Region
|
N/A | |
| Completed |
NCT02241005 -
Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci
|
N/A | |
| Recruiting |
NCT03689465 -
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
|
Phase 4 | |
| Recruiting |
NCT04868786 -
Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT03010579 -
Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation
|
Phase 4 |